10-Q: Charles River Labs Q2 Profit Plunges Amid Restructuring

Charles River Laboratories International, Inc. reported a significant decline in Q2 2025 net income and operating profit, primarily due to accelerated amortization and substantial restructuring costs, despite a slight revenue increase.

Summary

• Total revenue for the three months ended June 28, 2025, increased by 0.6% to $1,032.1 million, compared to $1,026.1 million in the prior year period.
• Total revenue for the six months ended June 28, 2025, decreased by 1.0% to $2,016.3 million, compared to $2,037.7 million in the prior year period.
• Operating income for the three months ended June 28, 2025, decreased by 34.0% to $100.1 million, with operating margin falling to 9.7% from 14.8% in the prior year.
• Operating income for the six months ended June 28, 2025, decreased by 37.0% to $174.8 million, with operating margin falling to 8.7% from 13.6% in the prior year.
• Net income attributable to Charles River Laboratories International, Inc. common shareholders decreased by 44.4% to $52.3 million for the three months ended June 28, 2025.
• Net income attributable to Charles River Laboratories International, Inc. common shareholders decreased by 53.4% to $77.8 million for the six months ended June 28, 2025.
• Diluted earnings per share (EPS) for the three months ended June 28, 2025, was $1.06, down from $1.74 in the prior year.
• Diluted earnings per share (EPS) for the six months ended June 28, 2025, was $1.55, down from $3.04 in the prior year.
• Cash flows from operations increased to $376.3 million for the six months ended June 28, 2025, up from $323.4 million in the corresponding period of 2024.
• The Research Models and Services (RMS) segment saw revenue increase by 3.3% and operating income increase by 19.5% for the three months ended June 28, 2025.
• The Discovery and Safety Assessment (DSA) segment experienced a 1.5% revenue decrease and an 11.3% operating income decrease for the three months ended June 28, 2025, due to cautious client spending.
• The Manufacturing segment's revenue increased by 4.4% for the three months ended June 28, 2025, but operating income plummeted by 67.6% due to accelerated amortization and restructuring costs.
• Restructuring charges totaled $32.2 million for the three months and $56.0 million for the six months ended June 28, 2025.
• The company expects approximately $225 million in annualized cost savings from restructuring actions, with approximately $175 million impacting fiscal year 2025.

Sentiment

Score: 3

Explanation: The overall sentiment is negative due to significant declines in operating income, net income, and EPS, driven by substantial restructuring costs and accelerated amortization from customer losses. While some legal issues are resolved and the RMS segment shows growth, the core profitability metrics are severely impacted, and cautious client spending persists in a key segment. The strategic review introduces uncertainty.

Positives

• The U.S. Department of Justice (DOJ) and U.S. Fish and Wildlife Service (USFWS) investigations into non-human primate (NHP) shipments from Cambodia have been closed, and the NHP shipments cleared for legal entry into the United States.
• Net cash provided by operating activities increased by $52.9 million to $376.3 million for the six months ended June 28, 2025, driven by lower variable compensation payments and favorable timing of supplier payments.
• The Research Models and Services (RMS) segment demonstrated revenue growth of 3.3% and a significant 19.5% increase in operating income for the three months ended June 28, 2025, with operating margin improving by 230 basis points.
• The company's Board of Directors approved a $1.0 billion stock repurchase authorization on August 2, 2024, with $549.3 million remaining as of June 28, 2025, indicating a commitment to shareholder returns.
• The company supports the FDA's pilot program to reduce animal testing, aligning with its Alternative Methods Advancement Project (AMAP) and 3Rs initiative, demonstrating adaptability to evolving industry standards.
• The CEO's employment term was extended to February 12, 2027, providing leadership stability.

Negatives

• Net income attributable to common shareholders decreased significantly by 44.4% for the three months and 53.4% for the six months ended June 28, 2025.
• Diluted EPS decreased by 39.1% for the three months and 49.0% for the six months ended June 28, 2025.
• Operating income decreased by 34.0% for the three months and 37.0% for the six months ended June 28, 2025, primarily due to accelerated amortization, restructuring activities, and higher legal/advisory costs.
• The Manufacturing segment's operating income decreased by 67.6% for the three months and 95.1% for the six months ended June 28, 2025, largely due to $35.5 million (Q2) and $71.0 million (YTD) in accelerated amortization from the loss of key CDMO customers.
• The Discovery and Safety Assessment (DSA) segment experienced lower volume and a decline in revenue and operating income due to continued cautious client spending in the current demand environment.
• DSA backlog slightly declined to $1.9 billion as of June 28, 2025, from $2.0 billion as of December 28, 2024, indicating ongoing demand challenges.
• Unallocated corporate costs increased by 30.8% for the three months and 4.3% for the six months ended June 28, 2025, due to higher third-party legal and advisory costs related to a Cooperation Agreement with a shareholder.
• Interest income decreased by 63.6% for the three months and 52.0% for the six months ended June 28, 2025, due to lower interest rates and interest-earning asset balances.
• Other income (expense), net, shifted from a net income of $3.6 million in the prior year to a net expense of $12.1 million for the six months ended June 28, 2025, primarily due to venture capital investment losses.
• The effective tax rate increased to 26.2% for the three months and 26.8% for the six months ended June 28, 2025, compared to 21.2% and 22.8% respectively in the prior year, primarily due to tax effects from stock-based compensation deductions and non-taxable remeasurement gains in the prior year.

Risks

• The ongoing U.S. Securities and Exchange Commission (SEC) inquiry related to the sourcing of non-human primates and related disclosures, with an unpredictable timing, outcome, or potential impact including fines, penalties, or liabilities.
• Putative securities class action lawsuit and derivative lawsuits against the company and certain current/former officers/directors related to NHP importation practices and disclosures, with an uncertain final outcome and potential for significant exposure.
• Continued cautious spending environment from global biopharmaceutical and biotechnology clients, particularly impacting the Discovery and Safety Assessment (DSA) segment, leading to potential revenue declines and reprioritization of drug pipelines.
• Impact of increased tariffs enacted by the U.S. government on imports from countries like Vietnam, Mauritius, and China, which could adversely affect operating margins and supply chain operations if costs cannot be fully offset by passing them to customers.
• Potential for new technologies, such as New Approach Methodologies (NAMs) and synthetically-manufactured products, to reduce or replace the demand for traditional animal models and animal-derived products in biomedical research, materially affecting business.
• Fluctuations in quarterly operating results due to changes in the global economy, product/service mix, government regulation, client buying patterns, financial performance of investments, and acquisition-related adjustments.
• The comprehensive strategic review process overseen by the Board's Strategic Partnership and Capital Allocation Committee may be time-consuming, costly, disruptive, and may not result in a transaction or outcome that benefits stockholders.
• Uncertainties related to the company's future during the strategic review process could lead to loss of business opportunities, stock price volatility, and difficulty attracting/retaining talent and partners.
• A reduction or delay in government funding of R&D, particularly from sources like the U.S. National Institutes of Health (NIH), could adversely affect revenue from academic institutions and research laboratories.
• Changes in government regulation or practices relating to the pharmaceutical or biotechnology industries, such as a relaxation in regulatory requirements or increased requirements that are difficult to satisfy, could reduce demand for services.

Future Outlook

The company anticipates approximately $225 million in annualized cost savings from ongoing restructuring actions, with about $175 million expected to impact fiscal year 2025. It plans to offset most of the estimated tariffs by passing along higher costs to customers. The company is continuously evaluating innovative approaches in drug development, including investments in virtual control groups and AI technologies, and is committed to collaborating with regulatory agencies and the biopharmaceutical industry to develop and implement new, non-animal based technologies. The SEC investigation timeline and outcome remain unpredictable, and the company cannot estimate potential fines or liabilities. The outcome of the securities class action and derivative lawsuits is also uncertain, with the company planning to vigorously defend against them.

Management Comments

• "We are continuing to see a cautious spending environment from our client base, principally within our DSA segment related to our global biopharmaceutical and biotechnology clients, as they reassess their budgets, reprioritize their drug pipelines, and manage their cost structures."
• "We expect that these effectuated actions, as well as other upcoming planned actions designed to optimize our global footprint to drive greater operating efficiency, will result in approximately $225 million of cost savings on an annualized basis, of which approximately $175 million will impact fiscal year 2025."
• "We support the FDA’s announcement as we believe the program aligns with the vision previously outlined in the FDA Modernization Act 2.0 and aims to develop a clearer regulatory pathway to streamline the drug development process and safely advance innovative technologies, including alternatives to the current animal based development process."
• "While we plan to offset most of the estimated tariffs by passing along these higher costs, we will continue to evaluate the nature and extent of the impacts to our business and our operating results."

Industry Context

The company operates within a global market environment characterized by cautious client spending, particularly among biopharmaceutical and biotechnology companies, leading to budget reassessments and drug pipeline reprioritizations. This trend has negatively impacted the Discovery and Safety Assessment (DSA) segment. The industry is also undergoing a shift towards alternative methods in preclinical safety studies, driven by initiatives like the FDA's pilot program to reduce animal testing, which aligns with the company's existing efforts in developing non-animal based technologies. Geopolitical factors, such as increased tariffs, are adding cost pressures, which the company aims to mitigate by passing costs to clients. The legal and regulatory landscape, particularly concerning non-human primate sourcing, continues to be a significant area of focus for the industry and the company.

Comparison to Industry Standards

• The company's strategic investments in virtual control groups for safety assessment studies and partnerships utilizing AI technologies are consistent with broader industry trends towards reducing animal use and enhancing efficiency in drug development, as advocated by the FDA Modernization Act 2.0 and the FDA's April 2025 pilot program.
• The company's Alternative Methods Advancement Project (AMAP), launched in April 2024, demonstrates a proactive approach to developing alternatives to animal testing, aligning with the industry's 3Rs (Replacement, Reduction, and Refinement) initiative.
• The company's efforts to explore recombinant versions of LAL, historically derived from live animals, and synthetically-manufactured products, reflect an industry-wide move towards more sustainable and ethical sourcing in testing products.
• The cautious spending environment observed in the DSA segment, leading to lower volume, is indicative of a broader macroeconomic trend affecting global biopharmaceutical and biotechnology clients, suggesting that the company's performance in this segment is influenced by wider industry budget constraints and reprioritization of drug pipelines.

Management Changes

Corporate Governance

Legal Proceedings

• U.S. Department of Justice (DOJ) and U.S. Fish and Wildlife Service (USFWS) investigations into non-human primate (NHP) shipments from Cambodia in late 2022 and early 2023 have been closed, and the NHP shipments cleared for legal entry into the United States.
• An ongoing inquiry from the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) requesting information related to the sourcing of non-human primates and related disclosures. The company is cooperating, but the timing, outcome, and potential impact (fines, penalties, liabilities) are unpredictable.
• A putative securities class action lawsuit filed on May 19, 2023, alleging materially false or misleading disclosures about NHP importation practices. The complaint was dismissed on July 1, 2024, but the plaintiff filed a notice of appeal on July 30, 2024, with oral arguments held on May 5, 2025. The company believes the lawsuit is without merit.
• Two derivative lawsuits filed on November 8, 2023, and August 2, 2024, asserting claims against Board members and certain current/former officers for alleged breaches of fiduciary duties related to NHP importation disclosures, internal controls, and ethics standards. These lawsuits are currently stayed pending developments in the securities class action appeal. The company believes these lawsuits are without merit.

Stakeholder Impact

• **Shareholders**: Significant decrease in net income and EPS, but ongoing stock repurchase program and strategic review aim to enhance long-term value. Legal proceedings and market conditions introduce uncertainty and potential volatility.
• **Employees**: Restructuring actions include workforce right-sizing, which may lead to job reductions and transition costs. Changes in compensation practices (lower variable compensation payments) are noted.
• **Customers**: Continued cautious spending from biopharmaceutical and biotechnology clients is impacting demand, particularly in the DSA segment. The company plans to pass on tariff-related cost increases, which could affect customer pricing.
• **Suppliers**: Favorable timing of payments to suppliers and vendors is noted, indicating efficient cash management.
• **Creditors**: Lower average debt balances contributed to decreased interest expense, which is positive for creditors. The company's liquidity is deemed sufficient to fund operations for the foreseeable future.

Next Steps

• Continue to implement restructuring actions to optimize global footprint and drive operating efficiency, aiming for $225 million in annualized cost savings.
• Evaluate the nature and extent of impacts from new tariffs and continue efforts to offset higher costs by passing them to customers.
• Cooperate with the ongoing U.S. Securities and Exchange Commission (SEC) inquiry related to non-human primate sourcing and disclosures.
• Vigorously defend against the putative securities class action lawsuit and derivative lawsuits, pending further developments in the appeal process.
• Continue to develop and implement new, non-animal based technologies in drug development, including virtual control groups and AI technologies, in collaboration with regulatory agencies and the biopharmaceutical industry.
• The Strategic Partnership and Capital Allocation Committee of the Board of Directors will oversee and direct a comprehensive strategic review and evaluation of the company's business and prospects.

Key Dates

Recommendation

The company's Q2 2025 results show a significant decline in profitability (operating income down 34%, net income down 44%) driven by substantial restructuring costs and accelerated amortization due to customer losses in the Manufacturing segment. While the closure of DOJ/USFWS NHP investigations is a positive, the ongoing SEC inquiry and class action lawsuits present continued legal and reputational risks. The DSA segment faces headwinds from cautious client spending. However, the company is actively implementing cost-saving restructuring initiatives expected to yield $225 million in annualized savings, and it has a significant stock repurchase program in place. The extension of the CEO's contract provides stability, and the strategic review could unlock future value. Given the mixed signals – severe short-term financial underperformance offset by proactive strategic measures and some positive legal developments – a 'Hold' recommendation is appropriate. Investors should monitor the effectiveness of restructuring, the outcome of legal proceedings, and the results of the strategic review before making further commitments.

Keywords

Biotechnology, Pharmaceutical, Drug Development, Contract Research Organization, CRO, Preclinical, Research Models, Safety Assessment, Manufacturing Solutions, SEC Filing, 10-Q, Non-Human Primates, NHP, Restructuring, Animal Testing Alternatives, Tariffs